BDR Pharma gets license pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country.
Last month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild to severe COVID-19 patients.
- Read more about BDR Pharma gets license pact with DRDO for 2-DG
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/bdr-pharma-gets-license-pact-with-drdo-for-2-dg
No comments:
Post a Comment